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Cancer is the second leading cause of death in the USA according to the American Cancer
Society. In the past 5 years, “theranostic nanomedicine”, for both therapeutics and imag-
ing, has shown to be “the right drug for the right patient at the right moment” to manage
deadly cancers. This review article presents an overview of recent developments, mainly
from the authors’ laboratories, along with potential medical applications for theranostic
nanomedicine including basic concepts and critical properties. Finally, we outline the
future research direction and possible challenges for theranostic nanomedicine research.
Copyright ª 2014, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. Open access under CC BY-NC-ND license. 1. Introduction
According to the American Cancer Society, approximately
1,660,290 new cancer cases are expected to be diagnosed in
2013 [1]. The American Cancer Society also projects that
580,350 will die from cancers in 2013, and cancer will account
for almost 1 in every 4 deaths. Early detection and effective
treatment of cancer is the key to saving lives. It is well docu-
mented that the major cause of cancer mortality is tumor
metastasis [2e10]. Because cancer cell dissemination mostly
occurs through the bloodstream via circulating tumor cells
(CTCs), scientists and medical professionals have beene or policy statement. No
istry and Biochemistry,
(P.C. Ray).
ministration, Taiwan. Publiworking to develop new approaches for early stage detection
of CTCs to help physicians treat patients and predict cancer
progression [11e25]. Although CTCs have been known since
1869, they can only be detected in patients with advanced
stage tumors [26e40]. Because CTCs are present at extremely
low levels, accounting for only a few cells/106 peripheral blood
mononuclear cells, it is a challenge for early detection. To
overcome this problem, effective separation and enrichment
is highly crucial [22e24,39,41e56]. Recent reports show that
use of nanomaterials as contrast agents and therapeutic ac-
tuators is one of themost promisingmethods, although this is
still at an infant stage [25,26,28,34,35,37,40,42,48,49,51,57e66].
Because nanoparticles exhibit unique optical, magnetic, andofficial support or endorsement by the FDA is intended or should
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detection as well as noninvasive photothermal therapy of
cancer [10e30]. During the past 5 years, it has been shown that
diagnosis and therapy can be combined within a single
multifunctional nanomaterial, known as “theranostic nano-
particles” [10e30]. The ideal theranostic nanomaterial should
possess several advantages [10e35]: (1) the ability for highly
selective accumulation in the diseased tissue, (2) capable of
delivering an effective therapeutic action selectively, and (3)
safe and can undergo biodegradation into nontoxic byprod-
ucts. We believe that development of effective theranostic
materials is one of the keys for detection and treatment of
early stage cancer in the 21st century. In this review, we will
highlight recent advances in the development of “theranostic
nanomedicine” mainly from the authors’ research. We will
also speculate on the future of research and technological
applications on theranostic nanomedicine.Fig. 1 e Scheme illustrating the combination of both
therapeutic and diagnostic functions into theranostic
nanomedicine.2. Theranostic nanomedicine
During the past decade, it has been demonstrated [5e20] that
nanoparticles of 4e100 nm, which are 1000e10,000 times
smaller than normal human cells, exhibit strong interactions
with biomolecules such as enzymes, receptors and antibodies,
both on the surface and inside the cell. By surface chemical
modification, nanoparticles can be coated, functionalized, and
integrated with a variety of bioconjugated moieties for selec-
tive detection and treatment [22e40]. Thus, we believe nano-
medicinewill lead breakthroughs for detection, diagnosis, and
treatment of cancer. Recent advances in nanoscience allow us
to design and place three functions, namely targeting, diag-
nosis, and therapeutics, into one nanomedicine [66e77].
Theranostic nanomedicine is based on this concept of
combining both therapeutic and diagnostic functions into one
nanoparticle, as shown in Fig. 1.3. Theranostic toolbox for CTC detection
Some tumor cells are continuously shed froma primary tumor
site into the vasculature to circulate in the blood system.
These are named CTCs, and are believed to account for the
growth and spread ofmetastasis tumors and to be responsible
for the majority of cancer-related deaths [2e10]. CTCs were
first observed in 1869 from the blood sample of a male meta-
static cancer patient by Thomas Ashworth, who assumed that
“cells identical with those of the cancer itself being seen in the
bloodmay tend to throw some light upon themode of origin of
multiple tumors existing in the same person” [10e20]. Due to
the ease of obtaining blood samples, detection of extremely
low concentrations of CTCs will lead to effective and mini-
mally invasive early stage diagnosis of cancer, as well as to
predict responses to therapy of patients with metastatic
cancers [10e20]. Despite the clinical importance of CTCs, the
isolation and enrichment of CTCs fromwhole blood remains a
challenge due to their extremely low concentrations in blood
[21e30].
To tackle this challenge, we have developed a multifunc-
tional plasmonic shell-magnetic core nanotechnology-drivenapproach for targeted diagnosis and isolation of cancer cells
[15,16]. Because noble metal nanoparticles exhibit unique and
versatile optical properties, there is a wide variety of contrast
mechanisms for cell optical imaging [21e30]. Plasmonic gold
nanoparticles have been widely used as agents for detection
and targeting [31e40]. Through the enhanced second har-
monic signal by antibody conjugated gold nanoparticles,
cellular imaging of single molecules has been reported [17].
For example, iron oxide magnetic nanoparticles have been
used as a contrast agent in magnetic resonance imaging and
biological separation [10e20]. As a result, the integration of
magnetic and plasmonic functions into a single platformwith
a magnetic core and a plasmonic shell should be hugely
beneficial for early stage CTC detection [15,16]. Plasmonic gold
coating on magnetic nanoparticles is very useful for stabiliz-
ing high-magnetic-moment nanoparticles under corrosive
biological conditions. It will also allow easy bioconjugation
through the well-understood chemistry of gold sulfide [15,16].
Magnetic core nanoparticles were synthesized by copreci-
pitation of Fe(II) and Fe(III) chlorides with 1.5 M NaOH as re-
ported recently [15,16]. Gold shells were formed by reduction
of Au3þ on the surface of iron oxide core (Fig. 2A). Formagnetic
separation of cancer cells followed by fluorescence imaging,
the magnetic/plasmonic nanoparticles surface was modified
with a cancer targeting aptamer. As shown in Fig. 2A, cyanine
3 (Cy3) modified S6 aptamers (specific targeting for the SK-BR-
3 cell line via HER25) were attached to magnetic/plasmonic
nanoparticles through eSH linkage. As reported previously
[15,16], the plasmonic shell was functionalized with aptamer-
modified Cy3 for: (1) specific breast cancer cell recognition via
the aptamers; and (2) fluorescent imaging using Cy3 as the
fluorescence probe. As shown in Fig. 2B, the magnetic core
was used for cell isolation. Specific cancer cell imaging and
separation for the human breast cancer cell line was based on
Fig. 2 e (A) Schematic representation showing synthesis of
S6 aptamer-conjugated multifunctional magnetic core-
gold shell nanoparticles. (B) Separation of specific cancer
cells using S6 aptamer-conjugated plasmonic/magnetic
nanoparticles. (C) Selective fluorescence imaging and
targeted photothermal destruction of specific cancer cells.
Note. From “Multifunctional plasmonic shellemagnetic
core nanoparticles for targeted diagnostics, isolation, and
photothermal destruction of tumor cells”, by Z. Fan, M.
Shelton, A.K. Singh, et al, 2012, ACS Nano, 6, p. 1065e73.
Copyright 2012, American Chemical Society. Reprinted with
permission.
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conjugated magnetic/plasmonic nanoparticles attach to can-
cer cells (Figs. 2C and 3) due to the S6 aptamer-cancer cell
interaction. To demonstrate the separation capability of very
low concentrations of cancerous cells (0.001%), 100 mL of S6
aptamer-conjugated magnetic/plasmonic nanoparticles with
1 mL of human epidermal growth factor receptor 2 (HER2)-
positive human SK-BR-3 breast cancer cell suspension con-
taining 100 cells/mL and 1 mL of HER2-negative human skincell HaCaT cell suspension containing 107 cells/mL were
incubated together. After 120 minutes of incubation at room
temperature under gentle shaking, the suspensions were
washed to remove unconjugated Cy3-bound magnetic/plas-
monic nanoparticles. Then the cancer cells were separated
from the suspension using a small magnet. Confocal fluores-
cence imaging was taken after magnetic separation (Fig. 3).
The imaging and separation of breast cancer cells from
normal cells can be achieved in 0.001% mixtures.
In addition, we have recently reported a targeted isolation
and detection of rare tumor cells from a whole blood sample
through a theranostic plasmonic shell-magnetic core star
shaped nanomaterial [16]. The theranostic core-shell star
shaped gold nanoparticles were synthesized through a two-
step process [16]. In the first step, very small spherical iron
nanoparticles were synthesized using trisodium citrate as a
stabilizer and sodium borohydride as a reducing agent [16]. In
the second step, star shaped magnetic nanoparticles were
synthesized using seed-mediated growth procedure in the
presence of cetyltrimethylammonium bromide [16]. Next, to
avoid nonspecific interactions with blood cells, star shaped
magnetic/plasmonic nanoparticles were coated by thiolated
polyethylene glycol (PEG) and then functionalized with an
aptamer. As shown in Fig. 4, the magnetic core was used for
cell isolation and enrichment. Cy3-modified S6 aptamerswere
attached to magnetic/plasmonic theranostic nanoparticles
througheSH linkage for: (1) specific SK-BR-3 breast cancer cell
recognition via the S6 aptamers; and (2) fluorescence imaging
using Cy3 as the fluorescence probe [16]. Due to surface
roughness, the star shaped magnetic-plasmonic particles can
enhance protein corona attachment, which can enhance
cellular uptake and magnetic separation capability.
The working principle for specific cancer cell separation
from whole blood sample is based on the fact that, in the
presence of the SK-BR-3 cell line, S6 aptamer-conjugated
theranostic nanoparticles were attached to the cancer cells
due to the S6 aptamerecancer cell interaction [16], as shown
in Fig. 5. To demonstrate the CTC separation fromwhole blood
samples, 0.001% SK-BR-3 human breast cancer cells were
spiked into the suspensions of citrated whole rabbit blood
samples. After 120 minutes’ incubation at room temperature
under gentle shaking, cells attachedwithmagnetic/plasmonic
nanoparticles were separated by a magnet (Fig. 5). Then cells
were diagnosed using fluorescence imaging (Fig. 5). Based on
these results, it is believed that the theranostic nanoparticles
can be used for imaging and separation of CTCs from the
whole blood sample even at 0.001% cell mixtures.
Detection of CTCs is not only based on positive enrich-
ment, but also a negative enrichment of CTCs using a
geometrically activated surface interaction chip as reported
by Hyun et al [21]. The geometrically activated surface inter-
action (GASI) chip with an asymmetric herringbone structure
is designed to generate enhancedmixing flows [21] to increase
the surface interaction between the nontarget cells and the
channel surface. After that, CD45 antibodies are immobilized
inside the channel to capture leukocytes and release CTCs to
the outlet. The report [21] shows that the GASI chip using a
herringbone shape can efficiently capture a large number of
hematological cells rather than CTCs (Fig. 6A). The herring-
bone structure is patterned on the channel to produce
Fig. 3 e (A) Fluorescent images of SK-BR-3 cancer cells after a mixture of LNCaP and SK-BR-3 cells (1:10L4 ratio) was
incubated with Cy3-modified S6 aptamer-conjugated magnetic/plasmonic nanoparticles and separated by a magnet. (B)
Bright-field image of the same SK-BR-3 cells after magnetic separation. (C) LNCaP cancer cell fluorescent images after a
mixture of LNCaP and SK-BR-3 cells (1:10L4) was incubated with Cy3-modified S6 aptamer-conjugated magnetic/plasmonic
nanoparticles and separated by a magnet. (D) Bright-field image of the same LNCaP cells after magnetic separation. (E)
Transmission electron microscopy image of SK-BR-3 cells after magnetic separation. It clearly shows that Cy3-modified S6
aptamer-conjugated magnetic/plasmonic nanoparticles are attached to SK-BR-3 cells. (F) Transmission electron microscopy
image of LNCaP cells separated by a magnet. Note. From “Multifunctional plasmonic shellemagnetic core nanoparticles for
targeted diagnostics, isolation, and photothermal destruction of tumor cells”, by Z. Fan, M. Shelton, A.K. Singh, et al, 2012,
ACS Nano, 6, p. 1065e73. Copyright 2012, American Chemical Society. Reprinted with permission.
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tigens on the cells and antibodies on the channel surface
(Fig. 6B and C) [21].
For CTC isolation, the GASI chip was tested using blood
samples from patients with several kinds of metastatic can-
cers [21]. Blood samples (1 mL) were collected from patients
with breast, lung, or gastric cancers. After the samples passedthrough the GASI chip, the collected cells were fixed on a glass
slide and stained with DAPI for DNA content, phycoerythrin-
conjugated cytokeratins for CTCs, and FITC-conjugated CD45
for leukocytes. After fluorescence imaging of the glass slides,
the captured images were carefully examined according to
predefined criteria (DAPI positive, cytokeratin positive, CD45
negative), as shown in Fig. 7. Because the negative enrichment
Fig. 4 e Schematic representation showing the synthesis of S6 aptamer-conjugate multifunctional theranostic magnetic
core-gold shell star shaped nanoparticles. Note. From “Theranostic magnetic coreeplasmonic shell star shape nanoparticle
for the isolation of the targeted rare tumor cells from whole blood, fluorescence imaging, and photothermal destruction of
cancer”, by Z. Fan, D. Sanapati, A.K. Singh, et al, 2012, Mol Pharm, 10, p. 857e66. Copyright 2012, American Chemical Society.
Reprinted with permission.
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such as size or molecular surface markers, but only specif-
ically removes nontarget cells [21], it can separate CTCs with a
variety of features (Fig. 7).4. Theranostic nanomedicine for cancer
therapy
Cancer nanotechnology therapeutics is different from sim-
ple carriers of drugs or biomolecules (i.e., proteins, siRNA)
[22]. Theranostic nanomedicine offers an opportunity toFig. 5 e Schematic representation showing the separation of spe
magnetic nanoparticles.Note. From“Theranosticmagnetic coreep
targeted rare tumor cells fromwhole blood, fluorescence imaging
Sanapati, A.K.Singh,et al, 2012,Mol Pharm,10, p. 857e66.Copyrighovercome limitations stated earlier. There are several po-
tential advantages of conjugate drugs with nanoparticles,
including targeted delivery of drugs to tumor sites [23],
controlled release of specific drugs at different locations
[24], and with increased half-life of drugs at disease sites by
changing their pharmacokinetic profile [25]. One way to
overcome these limitations is to engineer nanomaterials for
active binding to specific cells after extravasation. This se-
lective binding can be achieved by conjugating biomolecules
(antibodies, aptamers, peptide, etc.) with nanomaterials
through chemical bonding [26]. These functionalized nano-
materials will recognize and bind target cells, and the boundcific cancer cells using S6 aptamer-conjugated plasmonic/
lasmonic shell star shapenanoparticle for the isolationof the
, and photothermal destruction of cancer”, by Z. Fan, D.
t 2012,AmericanChemical Society. Reprintedwithpermission.
Fig. 6 e (A) Pictorial presentation of negative enrichment (side view). When the blood sample enters the inlet, the nontarget
cells (i.e., leukocytes) are specifically captured on the CD45 antibody-coated channels, whereas the target cells (i.e., CTCs) are
eluted through the outlet. The ridges on the top of the main straight channel create a helical flow that creates considerable
interaction between the cells and the antibody-coated channel surface. (B) A photograph of the fabricated GASI chip. The
GASI chip consists of an inlet, eight channels, and an outlet. Each channel is 2.1 mm in width and 50 mm in length. To
prevent breakdown of the PDMS channel due to their flexibility, a wall 400 mm in width bears the pressure. (C) The
herringbone structure and key parameters used in this study. Note. From “Negative enrichment of circulating tumor cells
using a geometrically activated surface interaction chip”, by K.A. Hyun, T.Y. Lee, and H.I. Jung. 2013, Anal Chem, 8, p.
4439e45. Copyright 2013, American Chemical Society. Reprinted with permission.
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drug is released. Another way is to skip chemotherapy and
apply other treatment methods, such as photothermal
therapy (PTT) and photodynamic therapy (PDT). PTT (use ofFig. 7 e Fluorescence images of cells isolated using GASI chip fr
cytokeratin-positive cells appear dual-positive with CD45. Note.
platform for targeted molecular imaging, molecular diagnostics
2011, Acc Chem Res, 44, p. 842e52. Copyright 2013, American Chheat to kill cancer cells) can be enhanced magnificently by
applying desired nanomaterials with near infrared light [27],
magnetic fields [28], and radio frequency [29]. PDT is also a
clinical treatment where tumor cells are killed by theom patients with metastatic cancers. For gastric cancer, all
From “Dextran-coated iron oxide nanoparticles: a versatile
, and therapy”, by C. Tassa, S.Y. Shaw, and R. Weissleder.
emical Society. Reprinted with permission.
Fig. 8 e An ex vivo optical image of major organs at 0.5 hours after intravenous injection of NOTA-mSiO2(DOX)-PEG-TRC105
in 4T1 tumor-bearing mice, which clearly showed stronger tumor DOX signal in the former. Note. From “In vivo tumor
targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles”, by F.
Chen, H. Hong, Y. Zhang, et al, 2013, ACS Nano, 7, p. 9027e39. Copyright 2013, American Chemical Society. Reprinted with
permission.
Fig. 9 e (A) 18F- fluorodeoxyglucose (FDG) positron emission tomographyecomputed tomography coregistered images of
mice intravenously administrated with aqueous suspensions of polyethylene glycol (PEG)ylated nanohexapods, nanorods,
nanocages, or saline. Tumors were treated either with (solid circleD left arrow) or without (solid circle) laser irradiation. (B)
18F-FDG standardized uptake values (SUVs) in laser-treated tumor and nontreated tumor. (C) Ratios of laser-treated tumor to
non-treated tumor 18F-FDG SUVs. Error bars are standard errors with n [ 3. Note. From “Comparison study of gold
nanohexapods, nanorods, and nanocages for photothermal cancer treatment”, by Y.Wang, K.C.L. Black, H. Luehmann, et al,
2013, ACS Nano, 7, p. 2068e77. Copyright 2013, American Chemical Society. Reprinted with permission.
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Fig. 10 e Bright-field inverted microscope images of multifunctional popcorn-shaped gold nanoparticle-conjugated LNCaP
prostate cancer cells. (A) prior to therapy and (B) after therapy for 30 minutes and stained with trypan blue. (C) Transmission
electron microscopy (TEM) images showing the deformation of cells after exposed to popcorn-shaped gold nanoparticle-
conjugated LNCaP cells and 100 mW, 785 nm NIR continuous-wave radiation for 10 minutes. (D) TEM image showing
structure deformation and irreparable damage of cancer cell surfaces after 20 minutes of radiation; purple circles show
bubble formation. (E) TEM image demonstrating irreparable damage of cancer cell surfaces when multifunctional popcorn-
shaped gold nanoparticle-conjugated LNCaP were exposed to 100 mW, 785 nm near infrared (NIR) continuous-wave
radiation for 30 minutes; purple circles show bubble formation. (F) Absorption profile demonstrating nanoparticle structural
changes after nanotherapy process. (G) Cell viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test
after popcorn-shaped gold nanoparticle-conjugated LNCaP cells, PC-3 cells, and HaCaT cells were exposed to 785 nm NIR
continuous-wave radiation at different doses. (H) Comparison of photothermal therapy responses between well-
characterized gold nanorods and popcorn-shaped gold nanoparticles whenmultifunctional nanoparticle-conjugated LNCaP
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nents, in addition to molecular oxygen in the tissue,
generate cytotoxic singlet oxygen under proper dosage.
Functionalized nanoparticle is complementary and supple-
mentary to PDT [30] and helps to reach deeper tissue that
PDT is not able to reach.5. Selective drug delivery and encapsulation
for chemotherapy
The application of gold nanoparticles as drug delivery vehicles
has been reported by several groups. More complex delivery-
related capabilities derived from functionalized nano-
particles, i.e., the administration of immunotherapy with a
targeting ligand [31], administration of a prodrug with its
activator enzyme [32]. The physiological microenvironment
[33], ultrasound [34], light [35], or radio frequency electro-
magnetic fields [36] could all be used to release drug
selectively.
In vivo enhanced anticancer drug delivery remains a
major challenge in cancer nanotechnology. Recently, the
development of functionalized uniform mesoporous silica
(mSiO2) nanoparticles for drug delivery in 4T1 murine
breast tumor-bearing mice has been reported by Chen et al
[37]. Besides gold nanoparticles, mSiO2 nanoparticle is an
alternative nanoplatform for selective drug delivery. In
that report, uniform mSiO2 nanoparticles were function-
alized with SH-PEG, TRC105 antibody (specific to CD105/
endoglin), Cu labeling and doxorubicin (DOX) [37]. After
intravenous injection of functionalized mSiO2 loaded with
DOX into 4T1 tumor-bearing mice, an IVIS spectrum in vivo
imaging system (excitation: 465 nm; emission: 580 nm)
was applied to check nanoparticle distribution in the
major organs (Fig. 8). The imaging showed the feasibility to
deliver a certain amount of drugs (like DOX) selectively to
the tumor site in vivo through functionalized mSiO2
nanoparticles [37].6. Selective near infrared light-induced PTT
Gold nanoparticles absorb light and convert photon energy
efficiently to heat, whichmakes them superior agents for PTT.
Gold nanoparticle-induced PTT has been popularly reported
and tested in recent years [38e43]. It was first reported in 2003
for PTT of lymphocytes in vitro by gold nanoparticles with a
nanosecond neodymium-doped yttrium aluminum garnet-
pulsed laser at 532 nm, which caused cell destruction [38].
When irradiated with the specific laser light, functionalized
gold nanomaterials will generate heat to kill cancer cells [39].
It was found that localized temperature increased to 70e80 C
through light absorption of gold nanoparticles [40] and around
150 antibodies were conjugated to PEG coated nanoshells [41].cells were exposed to 100 mW, 785 nm NIR continuous-wave ra
based targeted diagnosis, nanotherapy treatment, and in situ m
cancer cells using surface-enhanced Raman spectroscopy”, byW
18103e14. Copyright 2010, American Chemical Society. ReprintMost of these studies were targeted on either epidermal
growth factor receptor or HER2, because of the matched
monoclonal antibodies already approved by the US Food and
Drug Administration (FDA) for cancer therapy.
Because the absorbance wavelength of small gold nano-
spheres is not ideal for in vivo application, nanomaterials such
as gold nanorods, nanocages, and nanohexapods, which have
strong absorbance in the near infrared (NIR) range, have been
tested for in vivo photothermal therapy. The development of
gold nanohexapods as in vivo photothermal agents has been
reported recently [42]. The localized surfaceplasmonresonance
peaks of gold nanohexapods can be tuned by changing the
lengthof thearms toNIRrange forbetterpenetrationof the laser
into body tissues. In addition, photothermal effect of gold
nanohexapods was compared to those of gold nanorods and
nanocages. 18F-fluorodeoxyglucose (FDG) positron emission
tomographyecomputed tomography was applied to observe
tumormetabolism after targeted photothermal treatment with
nanomaterialsbyWangetal [42].After intravenous injectionsof
these three types of PEG coated gold nanomaterials or saline,
18F-FDG positron emission tomographyecomputed tomogra-
phy was performed prior to and after laser treatment. The 18F-
FDG uptake was distinctly reduced within laser treated tumors
compared to non-irradiated tumors (Fig. 9A). After the laser
treatment, substantial decrease of tumor standardized uptake
values were noticed, whereas the untreated tumors showed
constant metabolism (Fig. 9B). Nearly 90% reduction of tumor
metabolism in mice treated with nanohexapods or nanorods
and 80% decrease in mice treated with nanocages were
observed (Fig. 9C). These results demonstrate that all these PEG
coated gold nanomaterials could work as effective photo-
thermal agents for treatment of cancer.
The nanotechnology-driven, multifunctionalized gold
nanopopcorns can also be applied for targeted PTT treatment.
NIR radiation was applied for PTT. In this report [43], a
continuous-wavelengthportableOEM laser operating at 785nm
was used as the excitation light source for 30 minutes. After
that, a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) cell viability test was performed to find the
amount of live cells during the nanotherapy process. During
PTT, light absorbed by the gold nanoparticles is transferred to
the antibody, aptamer, and cell environment by rapid electron-
phonon relaxation in the nanoparticles, followed by phonon-
phonon relaxation [43e46]. This irradiation wavelength
matches the plasmon bands of the LNCaP cancer cell-
conjugated popcorn-shaped gold nanoparticles. As shown in
Fig. 10, exposure to the 785 nm light at 100 mW (12.5 W/cm2)
caused photothermal destruction of all the prostate cancer
cells. Transmission electronmicroscopy images (Fig. 10D and E)
of the irradiated cells clearly show areas ofmassive, irreparable
cell membrane disruption. After therapy, cell viability was
tested by MTT as well as bright-field inverted microscopy. Try-
pan blue was applied to determine the extent of cell death.
Fig. 10A shows that cells are 100% alive without therapy, butdiation for different times. Note. From “Gold nano-popcorn-
onitoring of photothermal therapy response of prostate
. Lu, A.K. Singh, S.A. Khan, et al, 2010, J Am Chem Soc, 13, p.
ed with permission.
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minutes of the nanotherapy process. The bright-field inverted
microscope image shows that the cancer cells aredeformeddue
to the nanotherapy process. This cell death following nano-
particles exposure to NIR radiation could be due to numerous
factors including nanoparticle explosion, shock waves, bubble
formation,and thermaldisintegration.Asshown inFig. 10Dand
E, bubbles are formed (indicated by purple circles) when
multifunctional popcorn-shaped gold nanoparticle-conjugated
LNCaP cells were exposed to 100 mW, 785 nm NIR continuous
wave radiation. As measured, the temperature increases to
48 Cduring the nanotherapy process. As shown in Fig. 10H, the
time-interval MTT test indicates that, within 30 minutes, most
of the cancer cells died. The same tests for the prostate specific
membrane antigen-negative prostate cancerous (PC-3) and
noncancerous (HaCaT) cells (Fig. 10G)were also performed. The
cancer cells required less than half the laser energy (8 W/cm2)
for photothermal lysis in comparison to the normal cells (20W/
cm2). To understand how good the PTT is with the popcorn-
shaped gold nanoparticles, the same photothermal experi-
ment with multifunctional gold nanorods (a ¼ 2.3) was per-
formed using 100mW, 785 nmNIR continuous-wave radiation.
Fig. 10H shows that photothermal response for nanopopcorn-Fig. 11 e (A) Bright-field inverted microscopic images of aptamer
SK-BR-3 breast cancer cells after irradiation with 670 nm light a
blue. (B) The same experiment as in (A) for SK-BR-3 cells. (C) Ce
plasmonic nanoparticles attached to SK-BR-3, MDA-MB, and HaC
minutes. (D) Cell viability when S-6 aptamer-conjugated magne
cell mixtures (1:0.01) were treated 670 nm light at 2.5 W/cm2 fo
shellemagnetic core nanoparticles for targeted diagnostics, iso
Fan, M. Shelton, A.K. Singh, et al, 2012, ACS Nano, 6, p. 1065e73
permission.based gold nanoparticles is comparable or slightly better than
that of the well-studied gold nanorods.
In addition to early detection and isolation of cancer cells,
multifunctional plasmonic shell-magnetic core nanoparticles
can also work as photothermal agent to kill cancer cells, as
reported recently [15]. Due to good biocompatibility, nontoxic,
andwith the ability to generate high temperatures at a desired
site, the greatest promise of plasmonic gold nanotechnology
medicine will be its use for early detection and therapeutics of
cancers [9,15,16,18,24,25,27,48,49,57e59]. Similarly, magnetic
nanoparticles can alsomediate localized hyperthermal effects
in the presence of a strong magnetic field [10e20]. In the
photothermal destruction experiment, 670 nm red light at
2e3 W/cm2 was used for 10 minutes’ irradiation. Because
biological systems mostly lack chromophores that absorb the
NIR light of 650e900 nm [48,49,51,58e71], 670 nm is particu-
larly useful in therapy for the induction of hyperthermia.
When S6-modified magnetic/plasmonic nanoparticles bound
to SK-BR-3 cells are excited with 670 nm light, due to the
strong absorption at this wavelength, photoexcitation of the
electron gas resulted in rapid nonequilibrium heating [15]. As
shown in Fig. 11A, most of the cancer cells were dead after 7
minutes of the nanotherapy process. Bright-field inverted-conjugated magnetic/plasmonic nanoparticles attached to
t 2.5 W/cm2 for 7 minutes followed by staining with trypan
ll viability when S-6 aptamer-conjugated magnetic/
aT cells were treated using 670 nm light at 2.5W/cm2 for 20
tic/plasmonic nanoparticles attached to SK-BR-3 and HaCaT
r 20 minutes. Note. From “Multifunctional plasmonic
lation, and photothermal destruction of tumor cells”, by Z.
. Copyright 2012, American Chemical Society. Reprinted with
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during the nanotherapy process. To understand how much
the temperature increases was during photothermal
destruction, thermal imaging was taken at 1-minute intervals
during the therapy process using a Mikro-Shot camera. The
temperature increased to about 55 C when exposing to
magnetic/plasmonic nanoparticle-bound cancer cells to a
670 nm laser at 2.5 W/cm2. By contrast, under the same con-
ditions, the temperature increased to only 35 C for MDA-MB
and LNCaP cancer cells without any nanoparticles.
As shown in Fig. 11C, the time interval cell viability test
indicated that, within 10 minutes, most of the SK-BR-3 cancer
cells were killed. By contrast, cell viability was more than 93%
in the MDA-MB and LNCaP cells and 96% for the HaCaT cells.
This is because the cancer cells are conjugated with the
magnetic/plasmonic nanoparticles with strong absorption at
the excitationwavelength of 670 nm [15]. As shown in Fig. 11D,
normal cells started to die after 6 minutes of therapy. At 13
minutes, about 100% of cancer cells were dead, only 12% of
normal cells were dead. In this way, this photothermal
destruction was highly selective.7. Selective combined therapy
PDT is one of the most important therapeutic options for
cancer and other diseases [47,49,60e62,71]. Despite itsFig. 12 e In vivo photodynamic therapy (PDT) and phototherma
(magnification 320). Normal or apoptotic cell nuclei are shown i
sections (GNReAlPcS4) complexD PDT and GNReAlPcS4 comple
cells during the staining procedure. (B) Tumor size after each th
phosphate buffered saline D PDT (n [ 7); free AlPcS4 D PDT (n
complex D PTT (n [ 5); GNReAlPcS4 complex D PTT D PDT (n
nanorodephotosensitizer complex for near-infrared fluorescenc
in vivo”, by B. Jang, J.Y. Park, C.H. Tung, et al, 2011, ACS Nano, 5
Reprinted with permission.advantage over traditional treatments, PDT has not been
accepted for general treatment in clinic [47,49,60e62,71].
There are several technical difficulties for the application of
PDT. First, the photosensitizers for PDT approved by the FDA
absorb light with wavelength below 700 nm, which does not
show good light penetration in the body [47,49,60e62,71].
Second,most existing photosensitizers aggregate easily under
physiological conditions. Third, the photosensitizers have low
selectivity to disease tissues [47,49,60e62,71].
Nanoparticles, by contrast, offer possible solutions for
theseproblems. Photosensitizer-conjugatednanoparticles can
be coated with PEG and modified with monoclonal antibodies
to selectively target the disease tissues [47,49,60e62,71].
Through two-photon excitation of the dyes encapsulated by
nanoparticles, it is possible to activate photosensitizers with
low energy light that can deeply penetrate tissues. The process
for delivery of photosensitizers is divided into passive and
active, based on the presence or absence of the targeting
molecules on the surface [23]. In this way, the methods to
deliver photosensitizers specifically to disease tissues are
named active, whereas othermethodswhich apply parenteral
administration and passive targeting (liposomes, polymeric
particles, and hydrophilic polymer-photosensitizer conju-
gates) are named passive [47,49,60e62,71]. Biodegradable
polymeric nanoparticles, which received tremendous atten-
tion as a possible method of delivering agents, are the main
passive carriers. The main advantages are high drug loadingl therapy (PTT). (A) TUNEL staining of the tissue sections
n green and brown, respectively. Empty areas in the tissue
xD PTTD PDT) are due to washout of the destroyed tumor
erapy session. Points, mean; bars, standard deviation;
[ 7); GNReAlPcS4 complex D PDT (n [ 7); GNReAlPcS4
[ 7); n [ number of tumors involved. Note. From “Gold
e imaging and photodynamic/photothermal therapy
, p. 1086e94. Copyright 2011 American Chemical Society.
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rials and manufacturing processes [45]. Photosensitizer
nanoparticles asonekindof active carriershavebeen the focus
of attention.Quantumdots arenanosized imagingprobeswithFig. 13 e (A) Bright-field inverted microscopic images of methyle
separatedbyamagnet followedby irradiationwith785nmnear IR
(B) Bright-field invertedmicroscopic images of LNCaP cells in the
light at 1W/cm2 for 20minutes followed by staining with trypan
LNCaP cells in the absence or presence of laser light. No cytotox
synergistic action in case of combined therapy. (D) Time-depend
1e2 W/cm2 for 35 minutes, in case of photodynamic, photothermhigh quantum yields, high photostability and fluorescent
emission ability which can be tuned by size. They can be syn-
thesized in aqueous solutions for a specific target to patho-
logical areas. Energy can be transferred to surrounding O2 byne blue (MB)-bound nanoplatforms attached LNCaP cell
light at 1W/cm2 for 7minutesandstainedwith trypanblue.
absence of nanoplatforms orMB and irradiatedwith 785 nm
blue. (C) Cell viability in MB-bound nanoplatforms attached
icity in the absence of NIR light. It also shows dramatic
ent cell viability after irradiationwith 785 nmnear IR light at
al, and combination therapy.
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application as photosensitizers has been explored in recent
reports [46].
A gold nanorod-photosensitizer conjugate was developed
for NIR photodynamic and photothermal combined therapy
in vivo [47]. When the gold nanorod (GNR) and the photosen-
sitizer conjugate are targeted to the surface of the tumor tis-
sue, the photosensitizers will be released from the GNR to
tissue surface and will generate singlet oxygen. The tumor
tissues can be selectively damaged by NIR laser irradiation
during targeted PDT while minimizing phototoxic tissue
destruction of surrounding healthy tissues. Therapeutic effi-
cacy of gold nanorod and photosensitizer conjugates can be
enhanced by extra photothermal therapy from gold nanorod.
A xenografted mouse tumor modal was applied to test the
combined therapy from a GNR-photosensitizer complex. After
intravenous injection with phosphate buffered saline, free
photosensitizer (tetrasulfonated aluminum phthalocyanine,
AlPcS4), and GNReAlPcS4 complex, in vivo therapeutic efficacy
was investigated. Tumor damage was not observed for phos-
phate buffered saline-injected mice after PDT and PTT
(Fig. 12A). AlPcS4-treated mice showed some tissue damage
after PDT. Mice injected with GNReAlPcS4 showed severe
tissue loss across a large tumor area. The efficacy of
GNReAlPcS4 treatment was also evaluated by measuring
tumor growth rates (Fig. 12B). Tumor growth decreased 79%
with PDT alone and 95% with combined PTT and PDT.
In addition, the theranostic plasmonic shell-magnetic core
star shaped nanomaterials was not only applied for targeted
isolation and detection of rare tumor cells from whole blood,
but also used as agents for combined synergistic photo-
thermal and photodynamic treatment of cancer. Several
groups have shown that magnetic core-plasmonic shell
nanoparticles can be used for PDT of cancer cell [48]. Methy-
lene blue is a well-known PDT agent [49]. The methylene-blue
bound magnetic core-plasmonic shell nanoplatform based
combined photodynamic and photothermal synergistic tar-
geted therapy of cancer was researched. The magnetic core
can be used for rare tumor cell isolation and enrichment.
Methylene blue-modified A9 aptamers are attached to nano-
platform through eSH linkage for: (1) specific LNCaP prostate
cancer cell recognition which overexpress prostate specific
membrane antigen, via the A9 aptamers [48]; (2) fluorescence
imaging using methylene blue as the fluorescence probe; and
(3) targeted PDT using methylene blue. By contrast, function-
alized nanoparticles have been used as a photothermal agent.
The existing results show that the cancer cells can be selec-
tively separated, imaged, and destroyed significantly by illu-
mination with 785 nm NIR continuum wave light for a few
minutes. Due to the synergistic effect, the therapeutic efficacy
of nanoplatformwas enhanced significantly compared to PDT
or PTT alone. Because the clinically ideal phototherapeutic
biological window for cancer is between 700 nm and 1100 nm
[50], the magnetic core-plasmonic shell nanoplatform has
strong absorption at 785 nm, the 785 nmNIR laser was applied
for combined synergistic therapy for cancer tumor. Bright-
field inverted microscope images (Fig. 13A) show that LNCaP
cancer cells are deformed during the combined therapy pro-
cess. The cell death following nanoplatform exposure to NIR
radiation could be due to numerous factors including reactiveoxygen species-induced cell death, nanoparticle explosion,
shock waves, bubble formation, and thermal disintegration.
Fig. 13B shows that the bright field inverted microscope im-
ages of LNCaP cells in the absence of nanoplatform and
methylene blue, after 20 minutes of exposure by 785 nm laser.
Bright field image andMTT test clearly showedno cell death in
the absence of nanoplatform. The nanoplatform-based com-
bined therapeutic killing is highly selective for the cells
attached with nanoplatform, and the combined therapy can
only be activated in the presence of NIR laser. Fig. 13C and D
show that when the two treatments were combined under a
single irradiation, the cell viability was remarkably reduced,
which is much lower than that treated individually.8. Cancer nanotechnology: future and
challenges
Nanomaterials are potential tools of tremendous benefits
that are now starting to be applied in the clinic. Targeting
ligands, imaging agents, and drug delivery can all be inte-
grated into one functionalized nanoparticle for targeted im-
aging and therapy. Thus multifunctionality is a unique
advantage of nanomaterials over traditional treatments.
Developing nanoparticle diagnosis and therapy in the right
directions will greatly improve the outcome of cancer pa-
tients. The future of cancer nanotechnology lies on a multi-
functional nanoplatform that combines both therapeutic
components and multimodality imaging. The ultimate goal is
that multifunctional nanomedicine works as efficient, tar-
geted in vivo drug delivery without systemic toxicity, and the
dose delivered as well as the therapeutic efficacy can be
accurately measured noninvasively with time. Much remains
to be done prior to when this can be transferred into the
clinic and many factors need to be optimized simultaneously
for the best clinical outcome.Conflicts of interest
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